Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 1/20 | 0.41 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.39 |
| ▸ | CDK7 | P50613 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ILK | Q13418 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL546253 | 0.89 | FGFR1 (0.45) | FGFR1FLT1CHEK1CDK7PARP1 | |
| SCHEMBL30060858 | 0.89 | FGFR1 (0.54) | FGFR1FLT1PARP1HDAC6ILK | |
| SCHEMBL28498762 | 0.89 | FGFR1 (0.54) | FGFR1FLT1PARP1HDAC6ILK | |
| SCHEMBL10240067 | 0.83 | L3MBTL1 (0.44) | FGFR1FLT1MAP3K8CHEK1CDK7 | |
| SCHEMBL12027128 | 0.81 | PKM (0.38) | FGFR1FLT1ALDH1A1KDM4EHPGD | |
| SCHEMBL6283876 | 0.81 | NT5E (0.35) | FGFR1FLT1CHEK1ALDH1A1KDM4E | |
| SCHEMBL28500906 | 0.81 | FGFR1 (0.44) | FGFR1FLT1ALDH1A1HTT | |
| SCHEMBL30059163 | 0.81 | FGFR1 (0.44) | FGFR1FLT1ALDH1A1HTT | |
| SCHEMBL10280194 | 0.81 | FGFR1 (0.54) | FGFR1FLT1CHEK1HDAC6KDM4E | |
| SCHEMBL13375019 | 0.80 | CBFB (0.43) | CHEK1PARP1ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778936-B2 | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8399442-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2013-03-19 | — | — | US | disclosed |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-07-26 | — | — | US | disclosed |
| US-8110573-B2 | Enzyme inhibitors; Cyclin-Dependent Kinases (CDK), Glycogen Synthase Kinases (GSK); -cyclopropyl-3-[3-(5-morpholin-4-ylmethyl-1H-benzoimidazol-2-yl)-1H-pyrazol-4-yl]-urea salt for example; anticancer agents | ASTEX THERAPEUTICS LIMITED (GB) | 2012-02-07 | — | — | US | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004232-A1 | Pharmaceutical Compounds | ERBB3, ABL1, RET | FGFR1 106/4885FLT1 324/4885MAP3K8 165/4885 |
| US-20120190673-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK3, CDK1, AURKA | FGFR1 1912/4885FLT1 2137/4885MAP3K8 121/4885 |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | CDK3, CDK1, AURKA | FGFR1 1912/4885FLT1 2137/4885MAP3K8 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.